Steroid eluting sinus stent

Intersect ENT Receives CE Mark Approval for PROPEL® Contour for Patients with Chronic Rhinosinusitis Following Frontal Sinus Surgery

Retrieved on: 
Thursday, May 20, 2021
Biotechnology, Surgery, Medical devices, Health, Pharmaceutical, Medical specialties, Branches of biology, Medicine, Otorhinolaryngology, Steroid eluting sinus stent, Sinus implant, Sinusitis, Propel, Frontal sinus, Sinus, Paranasal sinuses, Implant

The Contour CE approval expands the portfolio of PROPEL products available for commercialization inclusive of PROPEL and PROPEL Mini.

Key Points: 
  • The Contour CE approval expands the portfolio of PROPEL products available for commercialization inclusive of PROPEL and PROPEL Mini.
  • PROPEL Contour is specifically designed to maintain patency and reduce inflammation, and conform to the sinus ostia (openings) by focusing mechanical support and steroid delivery where it is needed to optimize sinus surgery outcomes.
  • It is the third localized drug delivery implant, completing the PROPEL family of drug-eluting, bioabsorable implants now available to ENT specialists in select EU countries.\nPROPEL Contour features an innovative hourglass shape, specifically designed for placement in the frontal sinuses (between the eyebrows) following sinus surgery for chronic rhinosinusitis patients.
  • A Corticosteroid-Eluting Sinus Implant Following Endoscopic Sinus Surgery for Chronic Rhinosinusitis: A UK-Based Cost-Effectiveness Analysis.

EXPAND Post-Market Study Evaluating Longer-Term Outcomes of PROPEL® Contour Sinus Implant in the Frontal Sinus Ostia Following In-Office Balloon Sinus Dilation

Retrieved on: 
Thursday, April 29, 2021
Science, Biotechnology, Research, Pharmaceutical, Surgery, Health, Medical devices, Clinical trials, Medical specialties, Clinical medicine, Branches of biology, Otorhinolaryngology, Headaches, Sinusitis, Sinus implant, Frontal sinus, Steroid eluting sinus stent, Ostium, Sinus, Mometasone

EXPAND is a prospective, randomized, single-blind, intra-patient controlled, post-market clinical trial enrolling approximately 80 patients in the United States.

Key Points: 
  • EXPAND is a prospective, randomized, single-blind, intra-patient controlled, post-market clinical trial enrolling approximately 80 patients in the United States.
  • The EXPAND study\xe2\x80\x99s primary objective is to evaluate the efficacy of the Company\xe2\x80\x99s PROPEL\xc2\xae Contour (mometasone furoate) sinus implant when placed in the frontal sinus ostium following in-office balloon dilation in patients with chronic rhinosinusitis (CRS) as compared to balloon sinus dilation alone.
  • There are approximately 150,000 balloon sinus dilation procedures performed annually in the United States with a substantial number of these procedures treating the frontal sinus ostia in ENT surgeons\xe2\x80\x99 offices.
  • Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection.

Intersect ENT to Report First Quarter 2021 Financial Results

Retrieved on: 
Tuesday, April 20, 2021
General Health, Health, Surgery, Medical devices, Steroids, Steroid eluting sinus stent, Mometasone, Intersect ENT, XC2, Sinus implant, Propel, Implant, Methasone

b'Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (\xe2\x80\x9cENT\xe2\x80\x9d) medical technology leader dedicated to transforming patient care, today announced that it will release first quarter 2021 financial results on Tuesday, May 4, 2021.

Key Points: 
  • b'Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (\xe2\x80\x9cENT\xe2\x80\x9d) medical technology leader dedicated to transforming patient care, today announced that it will release first quarter 2021 financial results on Tuesday, May 4, 2021.
  • To access the live conference call via phone, dial 844-850-0548 and ask to join the Intersect ENT call.
  • The Company\xe2\x80\x99s steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease.
  • For more information about PROPEL\xc2\xae (mometasone furoate) sinus implants and SINUVA\xc2\xae (mometasone furoate) sinus implant, please visit www.PROPELOPENS.com and www.SINUVA.com .\nIntersect ENT\xc2\xae, PROPEL\xc2\xae and SINUVA\xc2\xae are registered trademarks of Intersect ENT, Inc.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210420005271/en/\n'

Growth Opportunities in the United States Drug Eluting Sinus Stent Market to 2025, Featuring Intersect ENT, Inc., Johnson & Johnson, Medtronic plc and Stryker Corporation

Retrieved on: 
Monday, March 15, 2021
Medical technology, Medicine, Interventional cardiology, Medical devices, Medical equipment, Interventional radiology, Stent, Stryker Corporation, DES, Drug-eluting stent, Steroid eluting sinus stent

The US drug eluting sinus stent (DESS) market has increased significantly during the years 2018-2020, and projections are made that the market would rise in the next four years i.e.

Key Points: 
  • The US drug eluting sinus stent (DESS) market has increased significantly during the years 2018-2020, and projections are made that the market would rise in the next four years i.e.
  • The report provides an in-depth analysis of the US drug eluting sinus stent (DESS) market by value.
  • The US drug eluting sinus stent (DESS) market is concentrated with few major market players operating in the region.
  • The key players of the drug eluting sinus stent (DESS) market are Intersect ENT, Inc., Medtronic plc, Stryker Corporation (Entellus Medical, Inc.), and Johnson & Johnson (Acclarent, Inc.) are also profiled with their financial information and respective business strategies.

Intersect ENT to Participate at the Oppenheimer 31st Annual Healthcare Conference

Retrieved on: 
Wednesday, March 10, 2021
Surgery, Health, Medical devices, Steroids, Medical specialties, Intersect ENT, Steroid eluting sinus stent, Mometasone, ENT, Otorhinolaryngology, Sinus implant, Health care

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (ENT) medical technology leader dedicated to transforming patient care, today announced that Tom West, President & Chief Executive Officer, and Randy Meier, Executive Vice President & Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference.

Key Points: 
  • Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (ENT) medical technology leader dedicated to transforming patient care, today announced that Tom West, President & Chief Executive Officer, and Randy Meier, Executive Vice President & Chief Financial Officer, will participate in a fireside chat at the Oppenheimer 31st Annual Healthcare Conference.
  • Intersect ENT is a global ear, nose and throat medical technology leader dedicated to transforming patient care.
  • For more information about PROPEL (mometasone furoate) sinus implants and SINUVA (mometasone furoate) sinus implant, please visit www.PROPELOPENS.com and www.SINUVA.com .
  • Intersect ENT, PROPEL and SINUVA, are registered trademarks of Intersect ENT, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005176/en/

United States Drug Eluting Sinus Stent (DESS) Market Size, Trends & Forecasts 2021-2025 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 10, 2021
Health, Pharmaceutical, Interventional cardiology, Medical technology, Medicine, Medical devices, Medical specialties, Interventional radiology, Stent, DES, Cardiology, Drug-eluting stent, Steroid eluting sinus stent

The "The US Drug Eluting Sinus Stent (DESS) Market: Size, Trends & Forecasts (2021-2025 Edition)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The US Drug Eluting Sinus Stent (DESS) Market: Size, Trends & Forecasts (2021-2025 Edition)" report has been added to ResearchAndMarkets.com's offering.
  • The US drug eluting sinus stent (DESS) market has increased significantly during the years 2018-2020, and projections are made that the market would rise in the next four years i.e.
  • The report provides an in-depth analysis of the US drug eluting sinus stent (DESS) market by value.
  • The US drug eluting sinus stent (DESS) market is concentrated with few major market players operating in the region.

CMS Consolidates SINUVA Sinus Implant Coverage Under a Distinct Code, J7402, and Publishes an ASP Clarifying Payment and Easing Payer Coverage Adjudication

Retrieved on: 
Monday, March 8, 2021
General Health, Health, Medical devices, Steroids, Steroid eluting sinus stent, Pregnanes, Progestogens, Mometasone, Sinus implant, Implant

In January 2021, CMS created separate and distinct codes for Intersect ENTs two bioabsorbable implant product lines PROPEL (S1091) and SINUVA (J7402).

Key Points: 
  • In January 2021, CMS created separate and distinct codes for Intersect ENTs two bioabsorbable implant product lines PROPEL (S1091) and SINUVA (J7402).
  • CMS has now attached an ASP to J7402, mometasone furoate sinus implant, (sinuva), 10 micrograms.
  • We are pleased that CMS consolidated SINUVA coverage to a single code and published a SINUVA ASP.
  • For more information about PROPEL (mometasone furoate) sinus implants and SINUVA (mometasone furoate) sinus implant, please visit www.PROPELOPENS.com and www.SINUVA.com .

Intersect ENT Announces Launch of the New Straight Delivery System Packaged with the PROPEL® Mini Sinus Implant

Retrieved on: 
Thursday, February 11, 2021
Biotechnology, Audio, Video, Managed care, Hardware, Surgery, Health, Medical devices, Technology, Medical specialties, Steroids, Steroid eluting sinus stent, Intersect ENT, Branches of biology, Mometasone, Propel, Otorhinolaryngology, Sinus implant, Sinus, ENT, Ethmoid sinus

Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (ENT) medical technology leader dedicated to transforming patient care, today announced the U.S. availability of the new Straight Delivery System (SDS) packaged with the companys PROPEL Mini (mometasone furoate) Sinus Implant.

Key Points: 
  • Intersect ENT, Inc. (Nasdaq: XENT), a global ear, nose and throat (ENT) medical technology leader dedicated to transforming patient care, today announced the U.S. availability of the new Straight Delivery System (SDS) packaged with the companys PROPEL Mini (mometasone furoate) Sinus Implant.
  • It is specifically engineered for precise, consistent and easy delivery of the PROPEL Mini implant into the ethmoid sinus for maximum tissue apposition.
  • The original curved delivery system will continue to be available with the PROPEL Mini sinus implant, offering physicians a suite of options when using PROPEL Mini following sinus surgery.
  • Intersect ENT is pleased to provide our physicians with a complete package of PROPEL Mini and the Straight Delivery System, commented Thomas A.

Intersect ENT Announces CMS Approval of Coding Application for PROPEL® Sinus Implant

Retrieved on: 
Tuesday, January 19, 2021
General Health, Pharmaceutical, Health, Medical devices, Steroids, Steroid eluting sinus stent, Branches of biology, Sinus implant, Organ systems, Mometasone, Frontal sinus, Sinus, Maxillary sinus, Propel, Ethmoid sinus

The approval of this new application establishes a separate code for PROPEL, S1091 "Stent, non-coronary, temporary, with delivery system (propel), as well as updates the current SINUVA J-Code to, J7402 Mometasone furoate sinus implant, (sinuva), 10 micrograms.

Key Points: 
  • The approval of this new application establishes a separate code for PROPEL, S1091 "Stent, non-coronary, temporary, with delivery system (propel), as well as updates the current SINUVA J-Code to, J7402 Mometasone furoate sinus implant, (sinuva), 10 micrograms.
  • CMS will discontinue the original shared Level II HCPCS code J7401 "Mometasone furoate sinus implant, 10 micrograms.
  • For more information about PROPEL (mometasone furoate) sinus implants and SINUVA (mometasone furoate) sinus implant, please visit www.PROPELOPENS.com and www.SINUVA.com .
  • The PRROPEL sinus implants are indicated to maintain patency and locally deliver steroid to the sinus mucosa in patients >18 years of age after sinus surgery: PROPEL for the ethmoid sinus, PROPEL Mini for the ethmoid sinus/frontal sinus opening, and PROPEL Contour for the frontal/maxillary sinus ostia.

Peripheral Stent Implants Market to Close in on US$ 6 Bn by 2030, Driven by Increasing Peripheral Artery Disease Patient Pool Worldwide - Persistence Market Research

Retrieved on: 
Tuesday, January 12, 2021
Interventional radiology, Medical specialties, Medical devices, Medicine, Medical technology, Interventional cardiology, Stent, Steroid eluting sinus stent, Drug-eluting stent, Restenosis

Further, rising adoption of vascular stenting procedures is also surging demand for peripheral stents, propelling the growth of the global peripheral stent implants market.

Key Points: 
  • Further, rising adoption of vascular stenting procedures is also surging demand for peripheral stents, propelling the growth of the global peripheral stent implants market.
  • The global peripheral stent implants market is expected to exhibit a healthy CAGR of nearly 7% over the forecast period (20202030).
  • Higher peripheral artery disease patient pool and increasing adoption of peripheral vascular stents in Asian countries are expected to propel market growth in the region.
  • Get Full Access of Report: https://www.persistencemarketresearch.com/checkout/32225
    Manufactures in the peripheral stent implants market are actively focusing on launching new products to hold a better position in the peripheral stent implants market.